AstraZeneca PLC's CEO, Pascal Soriot, received 18,359 ordinary shares after a performance share award from May 2021 vested on May 14, 2026. This award...
Bullish
AstraZeneca plc remains a key player in global pharmaceuticals, with investors focusing on its first-quarter 2025 earnings and ongoing pipeline develo...
AstraZeneca has received US FDA approval for Baxfendy (baxdrostat), a first-in-class aldosterone synthase inhibitor, for adults with hypertension whos...
AstraZeneca's Enhertu has received two new FDA approvals for HER2-positive early breast cancer in both neoadjuvant and adjuvant settings, based on str...
Bullish
AstraZeneca PLC has received another FDA approval for its cancer drug Enhertu, expanding its use in a breast cancer indication. This decision, followi...
Neutral
QRG Capital Management Inc. lifted its holdings in Astrazeneca Plc (NYSE:AZN – Free Report) by 19.1% in the fourth quarter, according to its most rece...
Neutral
QRG Capital Management Inc. raised its position in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 19.1% in the fourth quarter, according to the...
Bullish
AstraZeneca surpassed first-quarter sales and profit estimates, largely due to strong demand for its cancer drugs. The company reaffirmed its 2026 fin...